Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2580

Sort by

Sort Order Select

Journal Articles

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Blood (2021) 138 (5): 387–400.

https://doi.org/10.1182/blood.2020008812

Published: 2021

Includes: Supplemental data

Journal Articles

Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL

Blood (2021) 137 (18): 2463–2480.

https://doi.org/10.1182/blood.2019004547

Published: 2021

Includes: Supplemental data

Journal Articles

Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study

Corentin Orvain, Marie Balsat, Emmanuelle Tavernier, Jean-Pierre Marolleau, Thomas Pabst, Patrice Chevallier, Noémie de Gunzburg, Victoria Cacheux, Françoise Huguet, Sylvain Chantepie, Denis Caillot, Yves Chalandon, Jamilé Frayfer, Caroline Bonmati, Véronique Lheritier, Norbert Ifrah, Hervé Dombret, Nicolas Boissel, Mathilde Hunault-Berger

Blood (2020) 136 (3): 328–338.

https://doi.org/10.1182/blood.2020004919

Published: 2020

Includes: Supplemental data

Journal Articles

FLT3 inhibitors added to induction therapy induce deeper remissions

Mark Levis, Wenge Shi, Ken Chang, Christian Laing, Reinhold Pollner, Christopher Gocke, Emily Adams, Flora Berisha, Jelveh Lameh, Arnaud Lesegretain

Blood (2020) 135 (1): 75–78.

https://doi.org/10.1182/blood.2019002180

Published: 2020

Includes: Supplemental data

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Blood (2019) 134 (Supplement_1): 693.

https://doi.org/10.1182/blood-2019-125120

Published: 2019

Journal Articles

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Blood (2019) 134 (Supplement_1): 601.

https://doi.org/10.1182/blood-2019-122141

Published: 2019

Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Blood (2019) 134 (Supplement_1): 695.

https://doi.org/10.1182/blood-2019-121694

Published: 2019

Journal Articles

Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches

Martin F. Kaiser, Matthew Jenner, MBBS, MRCP, FRCPath, David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Andrea Paterson, Rebecca Mottram, BA, BSc, Faith E. Davies, MD, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Gareth Morgan, MDPhDFRCP, Gordon Cook, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD

Blood (2019) 134 (Supplement_1): 604.

https://doi.org/10.1182/blood-2019-124819

Published: 2019

Journal Articles

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2019) 134 (Supplement_1): 580.

https://doi.org/10.1182/blood-2019-128519

Published: 2019

Journal Articles

Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

Brenda J Chyla, PhD, Jason Harb, PhD, Christine Mantis, PhD, Jacob J Riehm, PhD, Jeremy A. Ross, PhD, Yan Sun, PhD, Xin Huang, PhD MD, Qi Jiang, PhD, Monique Dail, PhD, Franklin V. Peale, Jr., MD PhD, Jalaja Potluri, MD, John Hayslip

Blood (2019) 134 (Supplement_1): 546.

https://doi.org/10.1182/blood-2019-128373

Published: 2019

Journal Articles

Serum Metabolomic Profiling Correlated with ISS and Clinical Outcome for Multiple Myeloma Patients Treated with High Dose Melphalan and Autologous Stem Cell Transplantation

Ljupco Veskovski, MD, Per-Ola Andersson, MD PhD, Ingemar Turesson, MD PhD, Daniel Malmodin, PhD, Anders Pedersen, PhD, Ulf-Henrik Mellqvist, MD PhD

Blood (2019) 134 (Supplement_1): 1771.

https://doi.org/10.1182/blood-2019-121961

Published: 2019

Journal Articles

VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis

Katrina M Piedra, PharmD, Hani Hassoun, MD, Larry W. Buie, PharmD, BCOP, FASHP, Sean M. Devlin, PhD, Jessica Flynn, BS, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sydney X Lu, MD PhD, Sham Mailankody, MBBS, Urvi A Shah, MD, Eric L Smith, MD PhD, Ola Landgren, MD PhD, Neha Korde, MD, Tim J Peterson, PharmD

Blood (2019) 134 (Supplement_1): 1835.

https://doi.org/10.1182/blood-2019-124403

Published: 2019

Journal Articles

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

Alex G Sieg, MD MS, Christopher Strouse, MD, Sarah L Mott, Joshua Reeder, Sergei Syrbu, MD PhD, Guohua An, MD PhD, Grerk Sutamtewagul, MD, Brian K. Link, MD, Umar Farooq, MD

Blood (2019) 134 (Supplement_1): 1626.

https://doi.org/10.1182/blood-2019-127349

Published: 2019

Journal Articles

Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1778.

https://doi.org/10.1182/blood-2019-127799

Published: 2019

Journal Articles

Lenalidomide Maintenance Prolongs Progression-Free Survival and Does Not Impact the Aggressiveness of Clinical Relapse: Data from Long-Term Follow up of the Myeloma XI Trial

Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, Kara-Louise Royle, MSc, David Cairns, MSc, PhD, Gordon Cook, Mark T Drayson, MB ChB, PhD FRCPath, Walter M Gregory, PhD, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Roger G. Owen, MD, Nigel H. Russell, MD, Gareth Morgan, MDPhDFRCP, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD

Blood (2019) 134 (Supplement_1): 1889.

https://doi.org/10.1182/blood-2019-126103

Published: 2019

Journal Articles

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Aparna Raval, PhD, Hearn Jay Cho, MD PhD, Cherie Green, BS, Elisabeth Wassner Fritsch, PharmD, Connie Ma, MS, Naomi Chang, MSc, Mark Yan, PhD, Mark Kockx, MD PhD, Shine Shen, MS, Ling-Yuh Huw, PhD, Emily Balestiere, BA, Marina Lipkind, BS, Huang Huang, MSc, Michelle Byrtek, PhD, Dawn Colburn, PharmD, BCOP, Sandy W. Wong, Jeffrey M. Venstrom, MD PhD, Joanne I Adamkewicz, PhD

Blood (2019) 134 (Supplement_1): 1907.

https://doi.org/10.1182/blood-2019-123652

Published: 2019

Journal Articles

Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting

Leila Jafari, Jubair Hussain, Ravi Krishnadasan, MD, Keri R Maher, DO, Faiz Anwer, MD, Emad Elquza, MD MBA, Christopher Campen, PharmD, Lauren Sanders, PharmD, Alyssa Henglefelt, PharmD, Alicia Ortega, PharmD, Ali McBride, PharmD,MS

Blood (2019) 134 (Supplement_1): 2153.

https://doi.org/10.1182/blood-2019-132121

Published: 2019

Journal Articles

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)

Tomoyuki Tanaka, Kiyomi Morita, MD, Feng Wang, PhD, Latasha Little, Curtis Gumbs, Jairo Matthews, Courtney D. DiNardo, MDMSc, Tapan M. Kadia, MD, Farhad Ravandi, MD, Marina Y Konopleva, MD PhD, Hagop M. Kantarjian, MD, Richard E. Champlin, MD, Guillermo Garcia-Manero, MD, P Andrew Futreal, PhD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 17.

https://doi.org/10.1182/blood-2019-122274

Published: 2019

Journal Articles

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, David Cairns, MSc, PhD, John R Jones, MD, Bhuvan Kishore, MB BS, MRCP, FRCPath, Mamta Garg, MD FRCP, FRCPath, Cathy Williams, MD MRCP, FRCPath, Kamaraj Karunanithi, MD FRCPath, Jindriska Lindsay, MD, MRCP, FRCPath, Nigel H. Russell, MD, Matthew Jenner, MBBS, MRCP, FRCPath, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Walter M Gregory, PhD, Martin F. Kaiser, Faith E. Davies, MD, Gareth Morgan, MDPhDFRCP

Blood (2019) 134 (Supplement_1): 1910.

https://doi.org/10.1182/blood-2019-126160

Published: 2019

Journal Articles

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Meena Bansal, DO, David S. Siegel, Jaeil Ahn, PhD, Rena Feinman, PhD, David H. Vesole, MD PhD, Joshua R Richter, MD, Andrew L. Pecora, MD, Elli Gourna Paleoudis, PhD, Scott D. Rowley, MD, Michele L. Donato, MD, Robert Korngold, PhD, Palka Anand, RN, BSN, CCRP, Laura McBride, RN, BSN, OCN, Kristin Ivanovski, RN, BSN, CCRP, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 1911.

https://doi.org/10.1182/blood-2019-125155

Published: 2019

NARROW

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL

Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study

FLT3 inhibitors added to induction therapy induce deeper remissions

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

Serum Metabolomic Profiling Correlated with ISS and Clinical Outcome for Multiple Myeloma Patients Treated with High Dose Melphalan and Autologous Stem Cell Transplantation

VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma

Lenalidomide Maintenance Prolongs Progression-Free Survival and Does Not Impact the Aggressiveness of Clinical Relapse: Data from Long-Term Follow up of the Myeloma XI Trial

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only